Author

L. Rasmussen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Organism:human· 1 Assay:metagenomics· 1 Organism:rat· 1 Organism:virus· 1

Frequent Co-Authors

R. Bostwick· 3 shared A. Simeonov· 2 shared C. Klumpp-Thomas· 2 shared C. Z. Chen· 2 shared D. C. Lo· 2 shared M. Shen· 2 shared P. Shinn· 2 shared W. Zheng· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

R. Bostwick

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Alcohol-Induced Mucociliary Dysfunction: Role of Defective CFTR Channel Function

L. Rasmussen, D. Stafford, J. LaFontaine, L. Antony, A. Allen, H. Kim, S. V. Raju

This study shows chronic alcohol use reduces CFTR activity and airway surface hydration, impairing mucociliary clearance and increasing respiratory infection risk.

bioRxiv · Jul 17, 2023 · PreprintPharmacology & Toxicology

Novel compound inhibitors of HIV-1NL4-3 Vpu

C. A. Robinson, T. D. Lyddon, H. M. Gil, D. T. Evans, Y. V. Kuzmichev, J. Richard, A. Finzi, S. Welbourn, L. Rasmussen, N. M. Nebane, V. V. Gupta, S. Ananthan, Z. Cai, E. R. Wonderlich, C. Augelli-Szafran, , M. C. Johnson

This study identifies two compounds that inhibit HIV-1NL4-3 Vpu activity but are strain-specific.

bioRxiv · Jul 30, 2021Microbiology

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

C. Z. Chen, P. Shinn, Z. Itkin, R. Eastman, R. Bostwick, L. Rasmussen, R. Huang, M. Shen, X. Hu, K. M. Wilson, B. Brooks, H. Guo, T. Zhao, C. Klumpp-Thomas, A. Simeonov, , W. Zheng

The paper identifies 319 compounds with anti-SARS-CoV-2 activities through a high-throughput screen, including 91 approved drugs and 49 investigational drugs, with 230 compounds previously unreported.

bioRxiv · Aug 18, 2020Microbiology

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators

K. Gorshkov, C. Z. Chen, R. Bostwick, L. Rasmussen, M. Xu, M. Pradhan, B. N. Tran, W. Zhu, K. Shamim, W. Huang, X. Hu, M. Shen, C. Klumpp-Thomas, Z. Itkin, P. Shinn, , W. Zheng

The paper identifies six autophagy modulators that block SARS-CoV-2 cytopathic effects in Vero-E6 cells with EC50 values between 2.0 and 13 µM.

bioRxiv · May 16, 2020Pharmacology & Toxicology